Trial reportBlood advances2025
Untangling profiles of postthrombotic syndrome using unsupervised machine learning.
Trial report in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01429714 (Individually Tailored Elastic Compression Therapy After Deep Venous Thrombosis in Relation to the Incidence of Post Thrombotic Syndrome, a Randomized Multicenter Trial), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Individually Tailored Elastic Compression Therapy After Deep Venous Thrombosis in Relation to the Incidence of Post Thrombotic Syndrome, a Randomized Multicenter Trial
Who cites it
3 citing papers in PubMed.
- Precision cardiovascular medicine with big data and AI.NPJ digital medicine · 2026Review
- Reassessing the Villalta score's use of signs and symptoms.Blood advances · 2025Article
- Artificial Intelligence in Orthopedic Surgery: Current Applications, Challenges, and Future Directions.MedComm · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractPostthrombotic syndrome (PTS) is a chronic condition that can develop after deep vein thrombosis (DVT) and is diagnosed using the Villalta scale. This study applied unsupervised machine learning to investigate the heterogeneity of PTS among patients and within the Villalta scale. In 818 patients from the IDEAL DVT study, clustering identified 4 clinical profiles: (1) younger patients with provoked DVT, (2) women with joint pain, (3) men with isolated popliteal DVT, and (4) older men with diabetes and femoral vein involvement. Clustering of Villalta items revealed a distinction between signs and symptoms. Sign scores increased with older age, male sex, higher body mass index (BMI), and DVT extent, whereas symptom scores increased with younger age, female sex, higher BMI, and provoked DVT. Residual venous obstruction was significantly associated with the sign score (odds ratio, 1.18 per point) but not the symptom score. Quality of life was related to the symptom score more than the sign score. At 6 months, sign and symptom scores differed significantly across profiles, especially between profile 1 and 4, because the former had most symptoms (41% vs 21% ≥ 3; P < .001), whereas the latter had most signs (18% vs 34% ≥ 3; P = .004]). After 2 years, symptoms decreased in profile 1 but increased in profile 4. Other profiles showed intermediate scores over time. These findings suggest that reappraising the PTS scoring system to distinguish its dimensions would enable more personalized risk prediction and prevention. This trial was registered at www.ClinicalTrials.gov as #NCT01429714.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.